Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults — VYF01  

Yellow Fever (Healthy Volunteers) Clinical Trial

Official title: Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults

Status Completed

Clinical Trial Summary

The primary objectives of the study are: - To describe the safety profile of each of the 3 dosages of vYF and of YF-VAX® within the 28 days post-vaccination and up to the 6 months (Day 180) post-vaccination visit - To describe the antibody responses elicited by each of the 3 dosages of vYF and by YF-VAX on Day 0 pre-vaccination and then on Day 10, Day 14, Day 28 and 6 months (Day 180) post-vaccination overall and by baseline flavivirus serostatus - To quantify the detectable yellow fever (YF) vaccinal viremia in each vaccine groups (vYF and YF-VAX) in a subset of subjects on Day 0 visit, Day 1 visit, Day 3 visit, Day 5 visit, Day 7 visit, Day 10 visit, and Day 14 visit.

Clinical Trial Description

Study duration per participant is approximately 6 months. ;

Related Conditions & MeSH terms

• Fever
• Yellow Fever
• Yellow Fever (Healthy Volunteers)

• NCT number: NCT04142086
• Study type: Interventional
• Source: Sanofi
• Status: Completed
• Phase: Phase 1
• Start date: January 15, 2020
• Completion date: June 24, 2021